Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Brigham and Women's Hospital Scios, Inc. |
---|---|
Information provided by: | Brigham and Women's Hospital |
ClinicalTrials.gov Identifier: | NCT00119691 |
The researchers hypothesize that the addition of nesiritide to standard therapy will prevent worsening of renal function in patients admitted to the hospital with decompensated heart failure and renal dysfunction relative to standard therapy alone.
Condition | Intervention | Phase |
---|---|---|
Congestive Heart Failure Renal Insufficiency |
Drug: Nesiritide |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Single Group Assignment, Efficacy Study |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Anju Nohria, MD | 617-525-6852 | anohria@partners.org |
Contact: Kimberly Brooks, RN | 617-732-6237 | kbrooks@partners.org |
United States, Massachusetts | |
Brigham and Women's Hospital | Recruiting |
Boston, Massachusetts, United States, 02115 | |
Contact: Kimberly Brooks, RN 617-732-6237 kbrooks@partners.org | |
Principal Investigator: Anju Nohria, MD |
Principal Investigator: | Anju Nohria, MD | Brigham and Women's Hospital |
Study ID Numbers: | 2003-P00235 |
Study First Received: | July 7, 2005 |
Last Updated: | July 13, 2005 |
ClinicalTrials.gov Identifier: | NCT00119691 History of Changes |
Health Authority: | United States: Institutional Review Board |
Natriuretic Peptide, Brain Heart Failure Renal Insufficiency Heart Diseases |
Urologic Diseases Cardiovascular Agents Kidney Diseases |
Natriuretic Peptide, Brain Renal Insufficiency Heart Failure Heart Diseases Urologic Diseases Natriuretic Agents |
Therapeutic Uses Physiological Effects of Drugs Cardiovascular Diseases Cardiovascular Agents Kidney Diseases Pharmacologic Actions |